| 1. |
Advances in the management of cirrhosis and ascites |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
WHO-approved randomised controlled trials (RCTs) will soon be available free on the Internet, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
For drug discovery, it is better to know which genes protect against a disease than which ones cause it, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Variation in opioid use suggests room for improvement |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
7-Valent pneumococcal conjugate vaccine at upper limit of good value |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Patient-controlled esomeprazole justified in GERD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
TH 9507*appears promising in patients with lipodystrophy associated with HIV infection, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
CJC 1131*[DAC: GLP-1] is effective in reducing glucose levels in patients with type 2 diabetes mellitus, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Intranasal ketamine relieves chronic breakthrough pain |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Intranasal fluticasone propionate superior to montelukast in allergic rhinitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1434,
2004,
Page 11-12
RM Poole,
Preview
|
|
摘要:
Fluticasone propionate nasal spray was more effective than oral montelukast in controlling nasal symptoms in patients with asthma and allergic rhinitis who were also receiving inhaled salmeterol/fluticasone propionate, according to results from a study presented at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. Both fluticasone propionate and montelukast provided significant improvements from baseline in nasal symptoms in this 4-week study; however, this effect was more marked with the fluticasone propionate nasal spray. Neither agent produced further improvements in morning peak expiratory flow (PEF), the primary efficacy endpoint for asthma control, compared with twice-daily doses of inhaled salmeterol/fluticasone propionate. Importantly, patients receiving intranasal fluticasone propionate reported higher levels of satisfaction with their study medication than those treated with montelukast.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
